Summary & Overview
HCPCS J7633: Budesonide Inhalation Solution for Nebulizer, per 0.25 mg
HCPCS Level II code J7633 designates a concentrated, FDA-approved budesonide inhalation solution supplied for administration through durable medical equipment (DME), billed per 0.25 milligram. This medication code matters nationally because inhaled corticosteroids delivered via nebulizer are widely used in management of obstructive airway diseases, and proper coding affects coverage, DME billing, and patient access to home respiratory therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for nebulized budesonide, typical sites of service (home and outpatient DME settings), and the billing landscape for an FDA-approved, non-compounded inhalation solution.
The publication provides national benchmarks and policy context relevant to medication DME billing, payer coverage considerations, and coding clarity for clinicians and billing staff. Where payer-specific guidance exists, coverage patterns and common administrative practices are summarized. Data not available in the input is noted where applicable. The goal is to give clinicians, revenue cycle staff, and policy analysts a clear, practical reference for HCPCS Level II code J7633 and its role in respiratory medication delivery via DME.
Billing Code Overview
HCPCS Level II code J7633 represents budesonide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per 0.25 milligram. This code describes a prescription inhalation corticosteroid product formulated for nebulized delivery.
-
Service type: Drug administration via durable medical equipment (nebulizer), medication supply
-
Typical site of service: Home or outpatient settings where durable medical equipment (DME) is used for aerosolized drug delivery
Clinical & Coding Specifications
Clinical Context
A 7-year-old child with persistent moderate asthma presents to a durable medical equipment (DME) infusion/respiratory therapy clinic for administration of inhaled corticosteroid therapy via a nebulizer. The child has difficulty with metered‑dose inhaler technique and is prescribed budesonide inhalation solution, concentrated formulation, to be administered through DME-provided nebulizer equipment in single or multiple treatment sessions. The clinical workflow includes verification of prescription for J7633, confirmation of patient identity and insurance, assessment of current respiratory status (wheeze, peak expiratory flow, oxygen saturation), teaching/review of nebulizer setup, administration of the measured 0.25 mg budesonide solution through the DME nebulizer, monitoring for adverse effects (tachycardia, oral thrush), documentation of medication lot number and amount administered, and communication of treatment and home instructions to the prescribing clinician.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | (No modifier) Standard reporting | Use when no special circumstances apply. |
22 | Increased procedural services | Use when additional work is required to prepare or administer therapy beyond typical practice (documented and justified).